Greenlane - GNLN Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Greenlane in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNLN shares.
View GNLN analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued twelve-month price targets for Greenlane's stock. Their GNLN share price forecasts range from $5.00 to $126.00. On average, they expect the company's share price to reach $43.40 in the next twelve months. This suggests a possible upside of 2,438.0% from the stock's current price.
View analysts price targets for GNLN or view top-rated stocks among Wall Street analysts.

Greenlane's stock was trading at $19.2820 at the beginning of the year. Since then, GNLN shares have decreased by 91.1% and is now trading at $1.71.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our GNLN earnings forecast.

Greenlane Holdings, Inc. (NASDAQ:GNLN) announced its quarterly earnings results on Tuesday, August, 16th. The company reported ($2.27) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $2.20. Greenlane had a negative net margin of 27.61% and a negative trailing twelve-month return on equity of 24.69%. During the same period last year, the firm earned ($0.10) EPS.

Greenlane's stock reverse split on Wednesday, August 10th 2022. The 1-20 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Greenlane investors own include KushCo (KSHB), OrganiGram (OGI), Enerplus (ERF), Matinas BioPharma (MTNB), Supreme Cannabis (SPRWF), ADMA Biologics (ADMA), EnLink Midstream (ENLC), Gran Tierra Energy (GTE), MariMed (MRMD) and Novan (NOVN).

(GNLN) raised $80 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Canaccord Genuity served as the underwriters for the IPO and Ladenburg Thalmann, Roth Capital Partners and Northland Securities were co-managers.

Greenlane trades on the NASDAQ under the ticker symbol "GNLN."

Greenlane's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Merlin Capital LLC (2.42%), Creative Planning (40.19%), AdvisorShares Investments LLC (0.68%), Millennium Management LLC (0.41%), AQR Capital Management LLC (0.15%) and State Street Corp (0.14%). Insiders that own company stock include Aaron Locascio, Adam Schoenfeld, Pura Vida Investments, Llc, Richard Taney and William E Mote Jr.
View institutional ownership trends.

Shares of GNLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GNLN stock can currently be purchased for approximately $1.71.

Greenlane (NASDAQ:GNLN) has a market capitalization of $10.95 million and generates $166.06 million in revenue each year. The company earns $-30,580,000.00 in net income (profit) each year or ($15.67) on an earnings per share basis.

The company employs 264 workers across the globe.

Greenlane's mailing address is 1095 BROKEN SOUND PARKWAY SUITE 300, BOCA RATON FL, 33487. The official website for the company is www.gnln.com. The company can be reached via phone at (877) 292-7660 or via email at investor@gnln.com.